Anti-Proliferative Effect of Specific Anti-EGFR Single Chain Antibody on Triple Negative Breast Cancer Cells | Zendy

Foroogh Abdollahzadeh | Zendy; Foroogh Nejatollahi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Anti-Proliferative Effect of Specific Anti-EGFR Single Chain Antibody on Triple Negative Breast Cancer Cells

Author(s) -

Foroogh Abdollahzadeh,

Foroogh Nejatollahi

Publication year - 2020

Publication title -

reports of biochemistry and molecular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.467

H-Index - 8

ISSN - 2322-3480

DOI - 10.29252/rbmb.9.2.180

Subject(s) - cetuximab , triple negative breast cancer , phage display , epidermal growth factor receptor , antibody , epitope , cancer research , panning (audio) , targeted therapy , microbiology and biotechnology , monoclonal antibody , cancer , chemistry , biology , breast cancer , immunology , medicine , paleontology , zoom , lens (geology)

Targeted therapy is an important treatment strategy that is widely used for cancer therapy. Epidermal growth factor receptor (EGFR) is overexpressed in a significant percentage of Triple-negative breast cancer (TNBC) patients. Although Cetuximab, which targets EGFR, has shown some inhibitory effects on TNBC cells, Cetuximab resistance cases due to ligand-independent activating mutations in the EGFR gene limit its application. Due to various benefits of single chain antibodies (scFvs), the use of these antibodies in cancer targeted therapy is increasing. In this study, a specific anti-EGFR antibody was isolated and evaluated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research